[go: up one dir, main page]

WO2015097667A3 - A combination of an akt inhibitor and at least one of cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor for treating cancer - Google Patents

A combination of an akt inhibitor and at least one of cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor for treating cancer Download PDF

Info

Publication number
WO2015097667A3
WO2015097667A3 PCT/IB2014/067274 IB2014067274W WO2015097667A3 WO 2015097667 A3 WO2015097667 A3 WO 2015097667A3 IB 2014067274 W IB2014067274 W IB 2014067274W WO 2015097667 A3 WO2015097667 A3 WO 2015097667A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
combination
akt
cyclooxygenase
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/067274
Other languages
French (fr)
Other versions
WO2015097667A2 (en
Inventor
Shireen VALI
Shahabuddin USMANI
Zeba SULTANA
Shweta KAPOOR
Ashish Kumar Agrawal
Taher ABBASI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Works Group Inc
Original Assignee
Cell Works Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Works Group Inc filed Critical Cell Works Group Inc
Publication of WO2015097667A2 publication Critical patent/WO2015097667A2/en
Publication of WO2015097667A3 publication Critical patent/WO2015097667A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to a pharmaceutical composition and a kit to treat cancer. The disclosure provides a composition comprising AKT inhibitor and at least one of cyclooxygenase-2 inhibitor and 5-lipoxygenase inhibitor. The disclosure further relates to a process of preparing the said composition and a method of treating cancer comprising PTEN mutation/AKT mutation/ PI3K mutation alone or in combination with each other or in combination with mutations in other genes causing cancer.
PCT/IB2014/067274 2013-12-23 2014-12-23 A composition, process of preparation of said composition, kit and a method of treating cancer Ceased WO2015097667A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN6014CH2013 2013-12-23
IN6014/CHE/2013 2013-12-23
IN746/CHE/2014 2014-02-17
IN746CH2014 2014-02-17

Publications (2)

Publication Number Publication Date
WO2015097667A2 WO2015097667A2 (en) 2015-07-02
WO2015097667A3 true WO2015097667A3 (en) 2015-11-26

Family

ID=53479742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/067274 Ceased WO2015097667A2 (en) 2013-12-23 2014-12-23 A composition, process of preparation of said composition, kit and a method of treating cancer

Country Status (1)

Country Link
WO (1) WO2015097667A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102766096B1 (en) * 2016-08-10 2025-02-12 에프. 호프만-라 로슈 아게 Pharmaceutical compositions comprising akt protein kinase inhibitors
JOP20180009A1 (en) 2017-02-06 2019-01-30 Gilead Sciences Inc Hiv inhibitor compounds
TWI766172B (en) 2018-07-30 2022-06-01 美商基利科學股份有限公司 Anti-hiv compounds
WO2023192941A2 (en) * 2022-04-01 2023-10-05 Drexel University Treating cancer with small molecules that inhibit acss-2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158197A2 (en) * 2010-11-11 2012-11-22 Lyndor Biosciences L.L.C. Compounds useful as akt/pkb modulators and uses thereof
US20130287763A1 (en) * 2010-07-28 2013-10-31 Merck Sharp & Dohme Corp. Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130287763A1 (en) * 2010-07-28 2013-10-31 Merck Sharp & Dohme Corp. Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
WO2012158197A2 (en) * 2010-11-11 2012-11-22 Lyndor Biosciences L.L.C. Compounds useful as akt/pkb modulators and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MCDOWELL KELLI A ET AL: "Targeting the AKT Pathway in Glioblastoma", CURRENT PHARMACEUTICAL DESIGN, vol. 17, no. 23, August 2011 (2011-08-01), pages 2411 - 2420, XP009183567 *
N NATHOO ET AL: "The eicosanoid cascade: possible role in gliomas and meningiomas", JOURNAL OF CLINICAL PATHOLOGY, vol. 57, no. 1, 1 January 2004 (2004-01-01), pages 6 - 13, XP055180533, ISSN: 0021-9746, DOI: 10.1136/jcp.57.1.6 *
S OBARA ET AL: "Integrin-linked kinase (ILK) regulation of the cell viability in PTEN mutant glioblastoma and in vitro inhibition by the specific COX-2 inhibitor NS-398", CANCER LETTERS, vol. 208, no. 1, 10 May 2004 (2004-05-10), pages 115 - 122, XP055180571, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2003.11.020 *
ZHANG JING ET AL: "Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo.", TECHNOLOGY IN CANCER RESEARCH & TREATMENT DEC 2009, vol. 8, no. 6, December 2009 (2009-12-01), pages 467 - 478, XP009183545, ISSN: 1533-0338 *

Also Published As

Publication number Publication date
WO2015097667A2 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
EP3881680B8 (en) Methods and compositions relating to microbial treatment
EP3134130A4 (en) Compositions and methods to treating hemoglobinopathies
HK1213889A1 (en) Glutaminase inhibitors and method of use
PH12012501838A1 (en) Aptamers to ãŸ-ngf and their use in treating ãŸ-ngf mediated diseases and disorders
EP3033091A4 (en) Method and compositions for treating cancer using probiotics cross-reference to related application
HK1214510A1 (en) Gla monotherapy for use in cancer treatment
EP3060207A4 (en) Methods and compositions for treating cancer
EP3153169A4 (en) Method for treating tumour, pharmaceutical composition and medicine box kit
EP3065549A4 (en) Methods for inhibiting tie2 kinase useful in the treatment of cancer
EP3072517A4 (en) Use of ginsenoside-rg3 in preparing medicine for preventing or/and treating dementia and medicine
EP3049536A4 (en) Methods and compositions relating to cancer therapy with dna damaging agents
MX377593B (en) Apilimod for use in the treatment of renal cancer
EP3082779A4 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
EP3004396A4 (en) Methods and compositions for the treatment of cancer
EP2970249A4 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
EP3007706A4 (en) Anti-mir-27b and anti-mir-148a oligonucleotides as therapeutic tools for treating dyslipidemias and cardiovascular diseases
EP3004395A4 (en) Compositions and methods for treating cancer
EP3250213A4 (en) Compositions containing arsenic and their use in methods of treatment
WO2015097667A3 (en) A combination of an akt inhibitor and at least one of cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor for treating cancer
EP3010504A4 (en) Methods and compositions to treat cancer
WO2015169811A3 (en) Anti-cxc chemokine receptor-2 binding molecules and uses thereof
IN2015DN00836A (en)
EP3380468B8 (en) Bis-pyridazine compounds and their use in treating cancer
EP2988737A4 (en) Methods and compositions for treating diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14833397

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 21.09.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14833397

Country of ref document: EP

Kind code of ref document: A2